Background {#Sec1}
==========

Interstitial lung disease (ILD) is the most common internal organ manifestation that affects the prognosis of clinically amyopathic dermatomyositis (CADM), as well as polymyositis (PM) and dermatomyositis (DM). ILD associated with CADM (CADM-ILD) is often refractory and rapidly progressive \[[@CR1]--[@CR3]\], resulting in respiratory failure with a 6-month survival rate of 40.8--54.5 % \[[@CR3]--[@CR5]\]. Although no standard treatment regimen for CADM-ILD has been established, intensive treatment with the three-drug combination of corticosteroid, cyclosporine, and cyclophosphamide is recommended in the early phase even if respiratory symptoms are absent or mild \[[@CR6], [@CR7]\].

Among patients with CADM, anti-melanoma differentiation-associated gene 5 (MDA-5) antibodies are strongly associated with the development of rapidly progressive ILD (RP-ILD) \[[@CR8]--[@CR10]\]. As MDA-5 plays the critical role in the innate immune defense against viruses, one hypothesis is that the production of anti--MDA-5 antibodies is a secondary phenomenon during virus infection that is associated with the onset of CADM and RP-ILD. However, to our knowledge, no previous study has revealed whether the presence or absence of the anti-MDA-5 antibody affects the clinical manifestation of CADM-ILD.

In the present study, we retrospectively reviewed consecutive cases of CADM-ILD to clarify the differences in the clinical features and prognosis between anti-MDA-5 antibody-positive and -negative cases, and to determine whether we should separate CADM-ILD by the presence or absence of anti-MDA-5 antibody.

Methods {#Sec2}
=======

Patients and settings {#Sec3}
---------------------

This retrospective study was performed at Kurashiki central hospital in Kurashiki city, Okayama, Japan. The patients diagnosed with CADM-ILD at our hospital from January 2005 to September 2014 who had cryopreserved blood serum before starting treatment were enrolled in this study. Diagnoses of CADM were made by at least two pulmonologists and one rheumatologist based on the criteria of Sontheimer \[[@CR11]\]. In addition, patients who exhibited a rash typical of DM without muscle weakness for less than 6 months and experienced fatal complications such as acute/subacute ILD were also diagnosed with CADM according to Gerami et al.'s criteria \[[@CR12]\]. No exclusion criteria were specified. The Ethics Committee of Kurashiki Central Hospital approved the study protocol. The Ethics Committee approved the waiver of each patient's consent because it was a retrospective study and high anonymity was secured.

Identification of myositis-specific antibodies {#Sec4}
----------------------------------------------

Measurement of myositis-specific antibodies was carried out by using cryopreserved blood serum before starting treatment. Serum anti-MDA-5 antibody was measured by immunoprecipitation using ^35^S-labeled HeLa cell extract (Perkin Elmer, Waltham, MA, USA), which was confirmed by enzyme-linked immunosorbent assay (SRL, Tokyo, Japan). Other myositis-specific antibodies, including anti-aminoacyl transfer RNA synthetase (anti-ARS) antibodies, were measured using the Myositis Profile Euroline antibody test system (EUROIMMUN, Lubeck, Germany), which was confirmed by RNA immunoprecipitation (Bio-Rad Laboratories, Hercules, CA, USA).

Clinical and laboratory findings {#Sec5}
--------------------------------

Clinical data and laboratory data used in the present study were retrieved from patient medical records and included gender, age, smoking history, length of time from onset of symptoms to first visit, department of the first visit, symptoms and physical examination, laboratory data, and results of bronchoalveolar lavage (BAL) and pulmonary function tests. BAL was routinely performed under local anesthesia before starting treatment. The bronchoscope was wedged into the segmental bronchi. Only samples with recovery \>25 % were used. With regards to pulmonary function test, forced vital capacity and diffusing capacity for carbon monoxide were measured using same machine and same method in all patients. Values were expressed as a percentage of the predicted value.

Radiological findings {#Sec6}
---------------------

All patients underwent high-resolution computed tomography (HRCT) at the time of diagnosis, and HRCT findings were reviewed and interpreted by board-certified pulmonologists and radiologists. Images were assessed for the dominant craniocaudal/axial distribution and the dominant shadow \[consolidation, ground-glass opacity (GGO), reticulation, or irregular linear opacity\]. The presence of traction bronchiectasis, cyst, subpleural curve linear shadow, thickening of the perilymphatic interstitium, emphysema, and loss in lung volume were also assessed. HRCT protocol and machine was the same for all included patients at peak tube voltage of 120 kVp and approximately ≤240 mAs using an automatic exposure control system (Toshiba Medical Systems, Tochigi, Japan).

Statistical analysis {#Sec7}
--------------------

Categorical data are presented as numbers (percentages), while continuous data are presented as medians (interquartile ranges). Fisher's exact test was used to compare categorical data, and the Mann--Whitney *U* test was used to compare continuous data. Cumulative survival probabilities were estimated using the Kaplan-Meier method. The log-rank test was used to compare survival among patient groups. A *p* value of \<0.05 was considered statistically significant.

Results {#Sec8}
=======

Characteristics {#Sec9}
---------------

From January 2005 to September 2014, we encountered 18 cases of newly diagnosed ILD associated with CADM. Anti-MDA-5 antibody was measured in 16 cases who had cryopreserved blood serum before starting treatment. Anti-MDA-5 antibody was present in 10 patients (positive group) and absent in 6 patients (negative group). Patients' characteristics are summarized in Table [1](#Tab1){ref-type="table"}. The median length of time from onset to first visit was shorter in the positive group (15.5 vs. 51.0 days, respectively), although the difference did not reach statistical significance (*p* = 0.157). No significant differences were observed in gender, age, smoking history, or symptoms and signs at the time of diagnosis between the two groups.Table 1Summary of clinical characteristicsMDA-5 positiveMDA-5 negative*p* value(*n* = 10)(*n* = 6)Gender (male/female)6/42/40.608Age63.0 (58.0--64.8)71.5 (64.8--73.8)0.0913Smoking history5 (50 %)2 (33 %)0.633Days from onset to first visit15.5 (11.0--29.8)51.0 (39.5--77.5)0.157Department of the first visit Respiratory medicine6 (60 %)1 (17 %)-- Rheumatology2 (20 %)5 (83 %)-- Dermatology2 (20 %)0--Symptoms and signs at the time of diagnosis Gottron's sign/papule7 (70 %)5 (83 %)1.00 Heliotrope eruption7 (70 %)1 (17 %)0.119 V/shawl neck sign5 (50 %)2 (33 %)0.633 Mechanic's hands2 (20 %)2 (33 %)0.604 Palmar erythema2 (20 %)1 (17 %)1.00 Myalgia3 (30 %)00.250 Dry cough5 (50 %)4 (67 %)0.633 Dyspnea on exertion5 (50 %)5 (83 %)0.307 Fever9 (90 %)3 (50 %)0.118Categorical data are presented as numbers (percentages) and were analyzed using Fisher's exact test. Continuous data are presented as medians (interquartile ranges) and were analyzed using the Mann--Whitney *U* test. A *p* value of \<0.05 was considered statistically significant*Abbreviation*: MDA-5, anti-melanoma differentiation-associated gene 5

Laboratory data {#Sec10}
---------------

Laboratory data are summarized in Table [2](#Tab2){ref-type="table"}. Aspartate aminotransferase (AST) and γ-glutamyl transpeptidase (γ-GTP) levels were significantly higher (*p* = 0.0225 and 0.00225, respectively) in the positive group when compared to the negative group, whereas serum levels of Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D) at the first visit were significantly lower (*p* = 0.0160 and 0.00402, respectively) in the positive group than in the negative group. In the positive group, serum KL-6 gradually increased, whereas serum SP-D remained consistently low 1--4 weeks after treatment initiation (Fig. [1](#Fig1){ref-type="fig"}). In the negative group, one patient each was positive for anti-Jo1 antibody, anti-PL-12 antibody, anti-OJ antibody, and anti-PM/Scl-100 antibody. Regarding BAL fluid analysis, the CD4^+^/CD8^+^ ratio was significantly higher in the positive group than in the negative group (*p* = 0.0167).Table 2Summary of the results of laboratory testing, bronchoalveolar lavage, and pulmonary function testMDA-5 positiveMDA-5 negative*p* value(*n* = 10)(*n* = 6)PaO~2~/FiO~2~ ratio296 (274--359)343 (332--357)0.689Laboratory data White blood cell count (/μL)5600 (4825--6300)8150 (5775--10150)0.573 Aspartate aminotransferase (IU/L)55.5 (40.5--92.3)28.5 (23.5--33.5)0.0225 Alanine aminotransferase (IU/L)27.0 (17.0--105)17.0 (16.3--19.3)0.252 γ-glutamyl transpeptidase (IU/L)40.5 (23.0--60.5)15.5 (14.0--22.3)0.00225 Creatine phosphokinase (IU/L)184 (90.3--467)108 (85.8--268)0.635 Aldolase (U/L)6.15 (3.58--8.45)7.50 (4.45--8.45)0.713 C-reactive protein (mg/dL)1.28 (0.90--2.94)0.62 (0.36--3.53)0.428 Lactate dehydrogenase (IU/L)368 (302--390)297 (259--331)0.0925 Krebs von den Lungen-6 (U/mL)600 (471--1072)1700 (1027--3511)0.0160 Surfactant protein D (ng/dL)32.5 (22.8--47.6)181 (98.1--378)0.00402 Anti-ARS antibody03 (50 %)  Anti Jo-101 (17 %)  Anti PL-1201 (17 %)  Anti 0 J01 (17 %) Anti-PM/Scl-100 antibody01 (17 %)Bronchoalveolar lavage Total cell count300 (250--400)500 (450--700)0.131 Neutrophil (%)3.00 (2.50--6.50)11.0 (8.50--51.5)0.0855 Eosinophil (%)1.00 (0.00--1.00)4.00 (2.00--5.50)0.284 Lymphocyte (%)30.0 (24.5--37.0)41.0 (22.0--42.0)0.819 Macrophage (%)60.0 (59.5--70.5)41.0 (23.0--44.0)0.0396 CD4+/CD8+ ratio1.68 (1.13--3.62)0.420 (0.340--0.490)0.0167Lung function test % Forced vital capacity79.8 (67.4--90.4)72.9 (53.4--93.6)1.00 % Diffusing capacity for carbon monoxide56.6 (50.2--63.7)56.9 (54.7--63.0)0.730Categorical data are presented as numbers (percentages) and were analyzed using Fisher's exact test. Continuous data are presented as medians (interquartile ranges) and were analyzed using the Mann--Whitney *U* test. A *p* value of \<0.05 was considered statistically significant*Abbreviation*: MDA-5, anti-melanoma differentiation-associated gene 5Fig. 1Chronological changes in serum KL-6 and SP-D. **a** Serum KL-6 levels at first visit and after 1--4 weeks' treatment initiation in each patient of the anti-MDA-5 antibody positive (left) and negative groups (right). **b** Serum SP-D levels at first visit and after 1--4 weeks' treatment initiation in each patient of the anti-MDA-5 antibody positive (left) and negative groups (right). Abbreviations: KL-6, Krebs von den Lungen-6; SP-D, surfactant protein D; MDA-5, anti-melanoma differentiation-associated gene 5

HRCT findings {#Sec11}
-------------

HRCT findings are shown in Table [3](#Tab3){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}. In both groups, there was a predominance of shadows in the lower lobe. Subpleural distribution was predominant in the positive group, whereas peribronchovascular distribution was predominant in the negative group. In the positive group, GGO (50 %) was the most commonly observed shadow followed by irregular linear opacity (30 %). Conversely, in the negative group, the most common shadow was consolidation with a significantly higher incidence than in the positive group (*p* = 0.00762). While HRCT findings in the positive and negative group often appeared to be mild, most were associated with loss of lung volume (90 and 83 %, respectively) or traction bronchiectasis (50 and 67 %, respectively).Table 3Comparison of HRCT findings between patients with and without anti-CADM-antibodyMDA-5 positiveMDA-5 negative*p* value(*n* = 10)(*n* = 6)Distribution Upper lobe dominant1 (10 %)01.00 Lower lobe dominant9 (90 %)6 (100 %)1.00 Peribronchovascular2 (20 %)4 (67 %)0.118 Subpleural8 (80 %)2 (33 %)0.118Main findings Consolidation1 (10 %)5 (83 %)0.00762 Ground glass opacity5 (50 %)00.0934 Reticulation1 (10 %)01.00 Irregular linear opacity3 (30 %)1 (17 %)1.00Additional findings Traction bronchiectasis5 (50 %)4 (67 %)0.633 Cyst01 (17 %)0.375 Subpleural curve linear shadow4 (40 %)3 (50 %)1.00 Thickening of interlobular septa2 (20 %)2 (33 %)0.604 Emphysema1 (10 %)1 (17 %)1.00 Volume loss9 (90 %)5 (83 %)1.00Categorical data are presented as numbers (percentages) and were analyzed using Fisher's exact test*Abbreviations*: *CADM* clinically amyopathic dermatomyositis, *HRCT* high-resolution computed tomography, MDA-5, anti-melanoma differentiation-associated gene 5Fig. 2High-resolution computed tomography findings. Representative photographs of HRCT scans are presented. **a** and **b** initial HRCT scans of fatal cases positive for anti-MDA-5 antibody showing subpleural GGO. (C) HRCT scans of an anti-MDA-5 antibody-positive patient who survived, showing subpleural irregular linear opacity. (D) HRCT scans of an anti-MDA-5 antibody-negative patient showing peribronchovascular consolidation. Abbreviations: GGO, ground-glass opacity; HRCT, high-resolution computed tomography; MDA-5, anti-melanoma differentiation-associated gene 5

Treatments and outcomes {#Sec12}
-----------------------

Three-drug combination therapy with corticosteroid, cyclosporine, and cyclophosphamide was the most common initial treatment in both groups (78 and 83 %, respectively). The median follow-up period over both groups was 689 days (the data cutoff date was November 9, 2014). In the present study, six deaths were observed during the follow-up period; all six cases were positive for anti-MDA-5 antibody and died from refractory ILD within 92 days from the first visit (median, 30.0 days). Five of these six cases received intensive initial treatment with corticosteroid, cyclosporine, and cyclophosphamide. The one remaining case was refractory to the initial treatment with corticosteroid monotherapy, and ~~thus~~ subsequently received cyclosporine and cyclophosphamide.

A comparison of survival curves is shown in Fig. [3](#Fig3){ref-type="fig"}. The anti-MDA-5 antibody-positive group had significantly lower survival rates than the negative group (*p* = 0.0252).Fig. 3Comparison of survival curves with and without anti-MDA-5 antibody. Cumulative survival probabilities were estimated using the Kaplan--Meier method. The log-rank test was used to compare survival among patient groups. A *p* value of \<0.05 was considered statistically significant. Abbreviation: MDA-5, anti-melanoma differentiation-associated gene 5

Comparison between survivors and non-survivors with anti-MDA-5 antibody {#Sec13}
-----------------------------------------------------------------------

A comparison between the survivors and non-survivors in the positive group is shown in Table [4](#Tab4){ref-type="table"}. The length of time from onset to the first visit was shorter among the non-survivors than the survivors, although this difference did not reach statistical significance (*p* = 0.0666). The length of time from onset to treatment initiation was significantly shorter in non-survivors than in survivors (*p* = 0.0381). As for the HRCT findings, the incidence of GGO was significantly higher among non-survivors than survivors (*p* = 0.0480). No significant differences were observed in terms of gender, age, smoking history, PaO~2~/FiO~2~ ratio, or BAL fluid analysis results between the two groups.Table 4Comparisons of characteristics and examination findings between anti-MDA-5-positive survivors and non-survivorsSurvivorsNon-survivors*p* value(*n* = 4)(*n* = 6)Gender (male/female)2/24/21.00Age58.5 (47.8--64.3)63.0 (59.3--64.5)0.519Time from onset to first visit29.5 (26.0--50.3)11.0 (11.0--13.3)0.0666 from onset to treatment initiation68.5 (31.5--107)16.0 (12.8--23.0)0.0381Symptoms and signs Gottron's sign2 (50 %)5 (83 %)0.500 Heliotrope eruption2 (50 %)5 (83 %)0.500 V/shawl neck sign1 (25 %)4 (67 %)0.524 Mechanic's hands02 (33 %)0.467 Palmar erythema02 (33 %)0.467 Myalgia2 (50 %)1 (17 %)0.500 Cough4 (100 %)1 (17 %)0.0480 Dyspnea on exertion3 (75 %)2 (33 %)0.524 Fever3 (75 %)6 (100 %)0.200Laboratory data Aspartate aminotransferase55.5 (36.8--76.8)55.5 (41.0--110)0.762 γ-glutamyl transpeptidase53.5 (43.5--57.5)28.0 (23.0--110)0.914 Krebs von den Lungen-61135 (930--1190)524 (470--626)0.114 Surfactant protein D45.3 (23.7--75.8)32.5 (24.2--40.9)0.669Bronchoalveolar lavage CD4+/CD8+ ratio3.52 (2.12--4.04)1.47 (1.20--2.19)0.857HRCT findings  Consolidation1 (25 %)00.400  Ground glass opacity05 (83 %)0.0480  Reticulation1 (25 %)01.00  Irregular linear opacity2 (50 %)1 (17 %)0.500Categorical data are presented as numbers (percentages) and were analyzed using Fisher's exact test. Continuous data are presented as medians (interquartile ranges) and were analyzed using the Mann--Whitney *U* test. A *p* value of \<0.05 was considered statistically significant*Abbreviations*: *HRCT* high-resolution computed tomography, MDA-5, anti-melanoma differentiation-associated gene 5

Discussion {#Sec14}
==========

Previous studies, mainly from Asia, have demonstrated that CADM-ILD often runs an aggressive course \[[@CR3]--[@CR5]\]. On the contrary, Cottin et al. reported good treatment response and favorable prognosis of CADM-ILD in France \[[@CR13]\]. These results suggest that CADM-ILD includes a heterogeneous disease population. The present study demonstrated the four following important clinical observations. First, serum KL-6 and SP-D at the first visit were significantly lower in the positive group than in the negative group. Second, serum AST, γ- GTP, and CD4^+^/CD8^+^ ratio in the BAL fluid were significantly higher in the positive group than in the negative group. Third, radiological findings were quite different between the two groups. Fourth, anti-MDA-5 antibody-positive cases had significantly lower survival rates than anti-MDA-5 antibody-negative cases. These clinical differences imply that anti-MDA-5 antibody-positive and -negative CADM-ILD should be regarded as separate entities.

The biomarkers ILD, KL-6, and SP-D are reportedly useful for assessing the prognosis of ILD in PM and DM \[[@CR14]--[@CR16]\]. However, the usefulness of KL-6 and SP-D in CADM-ILD has not been fully investigated in previous research. In the present study, serum levels of KL-6 at the first visit were lower in the positive group than in the negative group but gradually increased in most of the cases during the observation period. Although the cause is not clear, the two following reports may provide clues for resolving this problem. First, Otsuka et al. reported that in the early stage of acute exacerbation of idiopathic pulmonary fibrosis, the elevation in serum KL-6 mostly occurred after the manifestation of symptoms and deterioration of HRCT findings and the other biomarkers of ILD \[[@CR17]\]. Second, Sakamoto et al. reported that the serum levels of KL-6 are significantly correlated with the extent of traction bronchiectasis observed in HRCT, which is an indicator of the pathologic grade of fibrosis \[[@CR18]\]. As anti-MDA-5 antibody-positive cases tend to progress more rapidly compared with anti-MDA-5 antibody-negative cases, serum KL-6 levels may not yet have increased in anti-MDA-5 antibody-positive cases at the first medical examination. However, the higher values of KL-6 in the negative group might be somewhat affected by 2 subjects who have especially high KL-6 at first visit, thus we must be careful in interpreting the results. On the other hand, serum SP-D levels in the positive group were significantly lower than in the negative group and remained consistently low during the course of treatment. In the negative group, serum SP-D levels decreased after anti-inflammatory treatment in most of the cases. Several studies have reported that serum SP-D concentrations are correlated with the extent of alveolitis (most commonly reflected by increased cellularity in the alveolar interstitium), but not with the progression of fibrosis \[[@CR19]\]. Thus, low serum SP-D levels in the positive group may reflect poor cellularity and progressive fibrotic change, whereas high serum SP-D levels in the negative group may reflect relatively abundant cellularity.

As a background to the differences in the KL-6 and SP-D levels, we believe that immune reactions may differ in the lung between the two groups. The following two results support this supposition. 1) Serum levels of AST and γ-GTP were significantly higher in the positive group than in the negative group. Elevation of serum hepatobiliary enzymes was reported to be correlated with ILD in anti-MDA-5 antibody positive DM and CADM patients \[[@CR20]--[@CR22]\]. It was supposed that anti-MDA-5 antibody is associated with alveolar macrophage activation, thereby causing injury not only to the skin and lung, but also to the liver. 2) Furthermore, the CD4^+^/CD8^+^ ratio in the BAL fluid was significantly higher in the positive group than in the negative group. No previous reports have compared the results of BAL analysis between anti-MDA-5 antibody-positive and anti-MDA-5 antibody-negative CADM-ILD patients. Although it remains controversial whether the BAL lymphocyte subset is useful for clinical diagnosis of ILD, Suda et al. reported a higher CD4^+^/CD8^+^ ratio in patients with acute/subacute CADM-ILD than chronic CADM-ILD \[[@CR23]\]. Mukae et al. also showed a higher CD4^+^/CD8^+^ ratio in the BAL fluid of CADM patients than in those with classic DM \[[@CR5]\]. In addition, Ito et al. found a higher CD4^+^/CD8^+^ ratio in the BAL fluid of DM patients with RP-ILD than DM patients with chronic ILD \[[@CR24]\]. These results provide further confirmation of our data.

As well as laboratory data, radiological findings were quite different between the two groups. In the present study, the most common HRCT pattern in the positive group was lower subpleural GGO followed by subpleural irregular linear opacity. Although no previous reports have clarified HRCT findings of anti-MDA-5 antibody-positive CADM-ILD, Tanizawa et al. reported that the most common HRCT pattern in anti-MDA-5 antibody-positive DM-ILD is lower GGO/consolidation (50 %) followed by random GGO (33 %) \[[@CR22]\]. Irregular linear opacities were also reported to be typical in CADM-ILD \[[@CR13], [@CR23], [@CR25]\]. Intriguingly, the prevalence of GGO was significantly higher in non-survivors among anti-MDA-5 antibody-positive cases in the present study. Moreover, in one anti-MDA-5 antibody-positive case with subpleural GGO (as shown in Fig. [2a](#Fig2){ref-type="fig"}), autopsy revealed diffuse alveolar septal thickening due to organizing fibrosis, airspace organization, and hyaline membranes, suggesting a diffuse alveolar damage (DAD) pattern. Although no reports have evaluated the histopathological findings of treatment-naïve CADM-ILD with anti-MDA-5 antibody, the pathological findings of autopsied lung in CADM-ILD with anti-MDA-5 antibody mostly revealed a DAD pattern \[[@CR26]--[@CR28]\]. Therefore, GGO in HRCT of anti-MDA-5 antibody-positive CADM-ILD may reflect the histopathology of DAD. On the contrary, peribronchovascular consolidation, which is suggestive of nonspecific interstitial pneumonia or organizing pneumonia, was most frequently observed in the negative group. Such CT patterns are generally observed in ILD with classic DM; in fact, anti-ARS antibody was detected in 50 % of the negative cases.

These theories on the correlation between HRCT findings and pathological findings are supported by the differences in treatment response and prognosis between the two groups. The anti-MDA-5 antibody-positive cases had significantly lower survival rates than anti-MDA-5 antibody-negative cases; all six fatal cases were positive for anti-MDA-5 antibody and died from refractory ILD despite intensive initial treatment, whereas favorable treatment response and prognosis were observed in the negative group.

As described above, there are clear differences in the clinical features and prognosis between anti-MDA-5 antibody-positive and anti-MDA-5 antibody-negative CADM-ILD; thus, it would be appropriate to separate CADM-ILD by the presence or absence of anti-MDA-5 antibody. However, only a few medical facilities can measure anti-MDA-5 antibody levels, and it takes time to obtain test results; thus, the anti-MDA-5 antibody is not very helpful for deciding on a treatment policy and forecasting prognosis. Low levels of serum KL-6 and SP-D, high levels of serum AST, γ-GTP, and CD4^+^/CD8^+^ ratio in BAL fluid, and the predominance of subpleural GGO or irregular linear opacity in HRCT may provide clues for discriminating anti-MDA-5 antibody-positive CADM-ILD with poor prognosis. On the other hand, the clinical features of anti-MDA-5 antibody-negative CADM-ILD appear rather similar to those of classical DM-ILD, and, thus, should probably not be considered as a distinct clinical entity from classic DM; continuous monitoring of muscle and other clinical symptoms is required.

A limitation of the present study is the retrospective single-center study design. The number of included patients was small, and the distribution of patients may have been skewed. Another important limitation to this study is the risk of multiple comparison testing. Because of the high number of statistical tests in spite of small number of the patients, some of these will yield a *p*-value of \<0.05 by chance alone. As for ILD associated with CADM, there are regional and racial differences in the prevalence of ILD and the ratio of RP-ILD to the total population of CADM-ILD \[[@CR1]--[@CR4]\]. Additionally, the prevalence of anti-MDA-5 antibody is reportedly higher in Eastern Asia than in Europe or the US, although no previous studies have made direct comparisons \[[@CR20], [@CR21], [@CR24], [@CR29]--[@CR31]\].

Conclusions {#Sec15}
===========

Anti-MDA-5 antibody-positive and anti-MDA-5 antibody-negative CADM-ILD have clearly different clinico-radiological features and prognosis, and, thus, it would be appropriate to separate CADM-ILD by the presence or absence of anti-MDA-5 antibody. Further investigation with more cases is required to identify factors associated with poor prognosis among anti-MDA-5 antibody-positive CADM-ILD cases.
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